๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immune Thrombocytopenia
Clinical trial register · China

Immune Thrombocytopenia Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 15
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin15
All 1 locations
Target enrolment
to

Immune Thrombocytopenia trials in China

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
NCT07687134Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2026-07-10
Recruiting
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07362238Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
122
Tianjin
2026-03
Recruiting
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-03
Recruiting
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-28
Recruiting
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-20
Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08
Recruiting
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
NCT06776510Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-01-15
Recruiting
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-08-01
Recruiting
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2024-03-01
Active, closed
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT06199089Immune Thrombocytopenia, Treatment
DrugCM313
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-01-16
Recruiting
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-28
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06094881Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
NCT05995054Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
110
Tianjin
2023-08-28
Recruiting
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2022-02-15
Recruiting
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NCT04993885Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
52
Tianjin
2021-09-01
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/immune-thrombocytopenia

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition Immune Thrombocytopenia that also match the filters currently applied.

How many Immune Thrombocytopenia trials are recruiting in China?

13 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Immune Thrombocytopenia), 15 studies
PhaseStudiesRecruitingShare
Phase 2141293.3%
Phase 1/2116.7%

Most active sponsors

Lead sponsors with the most studies (Immune Thrombocytopenia)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China1513
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.